miR-4326 predicts adverse outcomes of triple-negative breast cancer and regulates cell growth and motility through modulating MED13

Key Points

• Adverse outcomes are linked to mir-4326 levels in triple-negative breast cancer, suggesting its role as a biomarker.
• Increased mir-4326 is associated with enhanced cell growth and motility, indicating aggressive behavior of tumors.
• Analysis used cell lines and clinical samples to explore mir-4326's effect on tumor biology and pathways.
• Highlights the potential for new therapeutic strategies targeting mir-4326 in triple-negative breast cancer treatment.